AVXL

Business Context and Reporting Period

Company: Anavex Life Sciences Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Stage: Development Stage Company (No revenue generated since inception in 2004).
Operations: Discovery and development of novel drug targets for cancer and neurological diseases (SIGMACEPTOR platform). Lead candidates include ANAVEX 2-73 (Alzheimer's/Epilepsy) and ANAVEX 7-1037 (Colorectal cancer).

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the three months ended March 31, 2009, increased to $1.24 million from $687,719 in the same period in 2008. The six-month loss increased to $2.17 million from $1.68 million.
• Expense Drivers:
  • Consulting Fees: Increased to $430,964 (3-month) and $971,531 (6-month) primarily due to increased stock-based compensation ($353,943 for the six months).
  • R&D Expenses: Increased to $328,859 (3-month) and $612,963 (6-month) due to increased research activity.
  • Debt Extinguishment: A one-time loss of $487,469 was recorded due to the renegotiation and extinguishment of a promissory note.
  • Legal Fees: Decreased significantly to $1,911 (3-month) from $42,805 in the prior year, attributed to non-recurring patent fees in 2008.
• Liquidity: Cash increased from $6,357 at September 30, 2008, to $78,729 at March 31, 2009, driven by financing activities (proceeds from promissory notes and private placements).
• Debt Restructuring: The company issued new unsecured promissory notes totaling approximately $1.92 million, some of which were used to settle matured debt.

Outlook, Risks, and Management Commentary

• Going Concern: Management and auditors express substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of over $9.2 million and expects to incur further losses. Continuation depends on obtaining additional financing.
• Capital Requirements: The company anticipates requiring up to $5.18 million for the 12 months ending March 31, 2010, primarily to fund clinical trials for lead compounds.
• Financing Activities:
  • Completed private placements in March 2009 raising $224,883.
  • Issued convertible promissory notes; $1.67 million of new loans were used to settle previously matured notes.
  • Defaulted on a $100,000 promissory note to a former officer as of March 31, 2009.
• Development Pipeline:
  • ANAVEX 2-73: Scale-up manufacturing initiated; clinical trials for Alzheimer's expected late 2009/early 2010.
  • ANAVEX 1-41: Phase 1 human trials expected to commence in 2010.
  • ANAVEX 7-1037: Advanced pre-clinical studies for colorectal cancer showing chemotherapeutic potential.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2009, citing existing weaknesses.
• Risk Factors: High risk of failure in clinical trials, inability to secure future funding, potential dilution of shareholders, and lack of commercial revenue history.

Investor Verification Checklist

• Debt Maturity & Default: Verify the status of the $100,000 defaulted note to a former officer and the terms of the $1.98 million in outstanding promissory notes (due on demand after early 2010).
• Cash Runway: Assess if the current cash balance of $78,729 is sufficient to cover operations until the anticipated $5.18 million funding is secured.
• Stock-Based Compensation: Review the valuation assumptions for the $353,943 in stock-based compensation and the impact of the 1.475 million outstanding stock options on future dilution.
• Going Concern Status: Confirm if any new financing agreements have been signed since the filing date to mitigate the "substantial doubt" expressed by auditors.
• Internal Controls: Evaluate the specific weaknesses in internal controls that led to the "not effective" conclusion and the timeline for remediation.